Google’s ven­ture arm leads Spero’s $51.7M round for R&D work on a pipeline of new an­tibi­otics

Cam­bridge, MA-based Spero Ther­a­peu­tics has com­plet­ed a C round worth $51.7 mil­lion, with Google’s ven­ture arm lead­ing the fundrais­ing for a biotech ini­tial­ly seed­ed at At­las.

The mon­ey will be ear­marked for the com­pa­ny’s work on new an­tibi­otics. In­ves­ti­ga­tors have moved in­to the clin­ic with SPR741, which used Spero’s plat­form po­ten­tia­tor tech to punc­ture the cell mem­branes of Gram-neg­a­tive bac­te­ria, open­ing a new door for Gram-pos­i­tive an­tibi­otics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.